TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Genotype-supported Versus Conventional Proton Pump Inhibitor Dosing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Pediatric:~Inclusion Criteria:~* 5-17 years of age~* diagnosed with GERD or any other stomach acid mediated condition for which a PPI treatment is provided~* currently under a Proton Pump Inhibitor (PPI) therapy or will start a PPI therapy~* Parents/legal guardians and or child must have access to internet and a valid email address~Exclusion Criteria:~* history of extensive esophageal or gastric surgery~* diagnosed with any major chronic illness or conditions that in the opinion of the gastroenterologist that would interfere with participation in the study~* history of Phenylketonuria (PKU) and patients with a history of previous adverse effects from PPI treatment or sensitivity to aspartame (NutraSweet, Equal)~Adult:~Inclusion Criteria:~* 18 years of age or older~* Gastroesophageal Reflux Disease symptoms~* Being initiated on PPI therapy OR continues to have symptoms despite PPI therapy~Exclusion Criteria:~* Extensive esophageal or gastric surgery~* Any chronic illness that would interfere with the study

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Adult Genotype guided treatment (Type: EXPERIMENTAL): For adults randomized to the genotype-supported arm a CYP2C19 genotype will be provided to physicians to assist in dosing.
- Adult Conventional treatment (Type: NO_INTERVENTION): For adults randomized to the conventional arm no genotype will be provided to physicians to assist in dosing.
- Pediatric Genotype guided treatment (Type: EXPERIMENTAL): For children randomized to the genotype-supported arm a CYP2C19 genotype will be provided to physicians to assist in dosing.
- Pediatric Conventional treatment (Type: NO_INTERVENTION): For children randomized to the conventional arm no genotype will be provided to physicians to assist in dosing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Resiliency Through Azithromycin for Children (REACH), Côte d'Ivoire

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
For expanded azithromycin access during the MDA~Inclusion Criteria:~* Child aged 1 month (at least 30 days) to less than 6 months at the beginning of the week of the MDA intervention~* Resident in study communities~Exclusion Criteria:~* Children below 3.0 kg~* Appears severely ill at the time of the MDA (per the CDD's assessment)~* Unable to swallow liquid delivered through a needle-less syringe because of physical limitations~* Known allergy to macrolides, including azithromycin, based on the primary caregiver's report of prior adverse reaction to medication likely to be a macrolide

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 5 Months
- Healthy Volunteers: t

Study Arms:
- Azithromycin (Type: OTHER): All children ages 1 to 5 months in the targeted health district will be offered a single dose of azithromycin suspension dosed at 20 mg per kg of weight in place of the standard tetracycline ointment, during a mass drug administration targeting trachoma prevention and treatment. All children ages 6 months and older, and all adults already receive the single dose of azithromycin during the MDA event. For this pilot study, single dose of azithromycin is being extended to include the 1 to 5 month old population as well.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Desvenlafaxine in Opioid-Dependent Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV-TR criteria for opioid dependence;~* Subject is on methadone treatment in the substitution program for at least 4 weeks;~* Subject is aged between 18 and 65 years old;~* subject meets the DSM-V TR criteria for major depressive episode, according to the study psychiatrist and confirmed by the Mini International Neuropsychiatric Interview (MINI);~* Subject reports a score of 20 or higher on the MADRS;~* Subject is eligible for and consents to the study;~* subject is able to give valid, informed consent;~* subject is able to speak and read French or English (grade-nine level of language required)~Exclusion Criteria:~* Unstable medical illness, defined as any medical illness which has not been well-controlled with standard-of-care medications;~* Severe psychiatric condition (e.g., current acute psychosis, past or current hypomania/mania) based on the MINI;~* Pregnancy or breastfeeding;~* Inability to use a medically acceptable form of contraception throughout the study duration. A medically acceptable form of contraception is either: (1) contraceptive pill or intrauterine device or depot hormonal preparation (ring, injection, implant); and/or (2) a barrier method of contraception such as diaphragm, sponge with spermicide or condom;~* Subject currently takes another antidepressant;~* Treatment with Desvenlafaxine at any time in the past;~* Known hypersensitivity to venlafaxine;~* Subject is undergoing psychotherapies for current depression (support therapy or counseling are allowed);~* Subject failed to respond to two or more Health-Canada-approved antidepressants during current episode;~* Unstable Axis-II personality disorder or other Axis-II disorder which has been the primary focus of treatment in the past 3 months, as ascertained by a study psychiatrists;~* Medical diagnosis of kidney and/or liver failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Desvenlafaxine (Type: OTHER): * Open-label pilot study~* Desvenlafaxine will be administered during 56 consecutive days~* Desvenlafaxine will be administered in the morning at a 50 mg dose during weeks 1 and 2, and at 50-100 mg doses (based on the study psychiatrist's judgment) during the 6 following weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Diclofenac Sodium Gel in Knee Osteoarthritis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Key Inclusion criteria~• Osteoarthritis of the knee~Key Exclusion criteria~* Other rheumatic disease, such as rheumatoid arthritis~* Active gastrointestinal ulcer during the last year~* Known allergy to analgesic drugs

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Screening laboratory result indicating hepatitis C virus (HCV) genotype (GT) 4, 5, or 6 infection.~2. Chronic HCV infection.~3. HCV treatment-naïve or treatment experienced (interferon \[IFN\] or pegylated interferon \[pegIFN\] with or without ribavirin \[RBV\]; sofosbuvir \[SOF\] plus RBV with or without pegIFN).~4. Non-cirrhotic participants.~Exclusion Criteria:~1. History of severe, life-threatening or other significant sensitivity to any excipient of the study drugs.~2. Female who is pregnant, planning to become pregnant during the study, or breastfeeding; or male whose partner is pregnant or planning to become pregnant during the study.~3. Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol in the opinion of the investigator.~4. Positive test result at Screening for hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus antibody (HIV Ab).~5. Co-infection with more than one HCV genotype.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ABT-493/ABT-530 (Type: EXPERIMENTAL): ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of Waldenström macroglobulinemia, splenic lymphoma with villous lymphocytes (SLVL), or non-IgM lymphoplasmacytic lymphoma based on morphological and immunophenotypic criteria~  * Bone marrow should be assessed by two-color flow cytometry for the expression of the following antigens:~    * Surface Ig~   * CD19~   * CD20~   * CD5~   * CD10~   * CD23~* Previously untreated disease requiring therapeutic intervention (as judged by the primary physician), as indicated by ≥ 1 of the following:~  * Hemoglobin \< 10 g/dL~ * ANC \< 1.5 x 10\^9/L~ * Platelet count \< 150 x 10\^9/L~ * Clinical evidence of hyperviscosity in terms of neurological or ocular disturbance~* Patients with disease detected by clonal cells alone are not eligible~PATIENT CHARACTERISTICS:~* Performance status 0-2~* Life expectancy \> 6 months~* Serum creatinine \< 200 mmol/L~* AST and ALT \< 2 times upper limit of normal~* Negative direct Coomb's test~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for ≥ 6 months after completion of study therapy~* No severe or life-threatening cardiac, pulmonary, neurological, psychiatric, or metabolic disease~* No other concurrent malignancy~* No AIDS or AIDS-related complex~* No evidence of active hepatitis C infection~PRIOR CONCURRENT THERAPY:~* Prior plasmapheresis for control of clinically significant hyperviscosity allowed~* Prior splenectomy for SLVL allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. Patients with confirmed histological or cytological diagnosis of advanced solid tumours and for whom no proven therapy exists or who are not amenable to established treatments.~2. Age 18 years or older.~3. Life expectancy of at least three months.~4. Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1.~5. Patients previously treated and with asymptomatic brain metastases are eligible~6. Patients must have recovered from recent surgery.~Exclusion criteria:~1. Active infectious disease~2. Recent surgery within the last 4 weeks prior visit 1.~3. Chronic diarrhoea or gastrointestinal tract disease resulting in an inability to take oral medication~4. History of haemorrhagic or thrombotic events~5. Significant cardiovascular diseases within~6. Current peripheral neuropathy \> Common Terminology Criteria for Adverse Events (CTCAE) grade 1 except due to trauma~7. Untreated or symptomatic brain metastases or leptomeningeal disease.~8. Treatment with an Epidermal growth Factor-receptor (EGFR)- or Heregulin Receptor 2 (HER2) inhibiting drug or antiangiogenic drug.~9. Therapeutic anticoagulation.~10. Female patients of childbearing potential.~11. Known pre-existing interstitial lung disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BIBW 2992 + BIBF 1120 (Type: EXPERIMENTAL): This is a phase I dose escalation clinical trial and the data obtained shall determine the MTD for the combination of BIBW 2992/BIBF 1120 in 28-day of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Changes of Macular Pigment and Parameters of Eyes After YAG Laser Treatment in Cases With Capsule Opacification

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Best-corrected visual acuity (BCVA) logMAR \<0.3~* Duration at least 2 years after cataract surgery~* Between the ages of 45 and 65 years (45≤age≤65)~Exclusion Criteria:~* Corneal scarring, diffuse posterior PCO or intravitreal hemorrhage that prevents appearance of the fundus~* Occluded angle by gonioscopy (grade 0, narrow angle, grade I, grade II)~* Presence of macular or peripheral retinal pathologies or choroidopathy~* High risk for RD~* Presence of macular edema in the macular area~* Detection of macular fluid or edema in OCT~* Active intraocular inflammation~* Previous laser PRP, Nd: YAG laser posterior capsulotomy, laser iridotomy or selective laser trabeculoplasty interventions~* Previous iridectomy, glaucoma or vitreoretinal surgery~* Glass intraocular lens~* Spherical refractive error ≥ ±6.00 D or cylinder refractive error ≥ ±3.00 D~* Inadequate stability of the eye~* Systemic diseases that may affect the choroidal blood flow such as cardiological diseases~* Current use of carotenoid supplementation~* Changing eating habits~* Gastrointestinal diseases that could cause disturbance of dietary absorption

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Nd: YAG laser posterior capsulotomy (Type: EXPERIMENTAL): Posterior capsulotomy was performed by using Nd: YAG laser and macular pigment optical density, intra ocular pressure, choroidal thickness, macular thickness and anterior chamber parameters were measured before Nd: YAG laser, at 1 week, 1 month and 2 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Observation PMS for Afatinib

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~- Patients with Epidermal Growth Factor Receptor (EGFR) mutation-positive inoperable or recurrent non-small cell lung cancer (NSCLC)will be included.~Exclusion criteria:~- None

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Afatinib (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Zalutumumab in Head and Neck Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of squamous cell carcinoma of the oral cavity, nasal cavity, paranasal sinuses, nasopharynx, oropharynx, hypopharynx or larynx.~* Primary or recurrent disease for which no curative or established palliative treatments are amenable~* WHO performance status of 1 or 2.~Exclusion Criteria:~* Received certain other treatments within 4 weeks prior to administration of study drug~* Previous severe allergic reactions (e.g. angio-edema, severe asthma, or anaphylaxis).~* Skin disease requiring systemic or local corticosteroid therapy.~* Known brain metastasis or leptomeningeal disease.~* Signs or symptoms of acute illness.~* Bacterial, fungal or viral infection.~* Certain serious medical conditions, including kidney or liver disease, some psychiatric illnesses, myocardial infarction within one year and stomach, lung, heart, hormonal, nerve or blood diseases.~* Pregnant or breast-feeding women.~* Women of childbearing age who are unable or unwilling to use an IUD or hormonal birth control during the whole trial.~* Simultaneous participation in any other trial involving investigational drugs or having participated in a trial within 4 weeks prior to start of trial treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zalutumumab 0.15 mg/kg (Type: EXPERIMENTAL): None
- Zalutumumab 0.5 mg/kg (Type: EXPERIMENTAL): None
- Zalutumumab 1 mg/kg (Type: EXPERIMENTAL): None
- Zalutumumab 2 mg/kg (Type: EXPERIMENTAL): None
- Zalutumumab 4 mg/kg (Type: EXPERIMENTAL): None
- Zalutumumab 8 mg/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chlorhexidine vs. Iodine for Vaginal Preparation in Urogynecologic Procedures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female Subjects \>18 years of age~* English or Spanish speaking/reading~* Must be able to provide informed consent~* Undergoing urogynecologic procedures or surgery~Exclusion Criteria:~* Pregnant - all patients are verified regarding pregnancy status prior to gynecologic surgical intervention at all sites of surgery - for patients who are premenopausal and have a uterus, a urine pregnancy test is administered in the preoperative setting. Pregnancy status is also determined prior to this in the office setting by interview and patient provided history prior to offering surgery to the patient.~* Inability to return for follow-up visits~* No concurrent need for vaginal antisepsis, such as cases of sacral neuromodulation~* Lack of telephone~* Known allergy to either antiseptic agent~* Prisoners will not be eligible to participate in this study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Chlorhexidine gluconate (Type: EXPERIMENTAL): Chlorhexidine gluconate 2% vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
- Povidone Iodine (Type: ACTIVE_COMPARATOR): Povidone iodine vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Success of Transitioning Uncontrolled Glaucoma Patients From Prior Mono or Adjunctive Therapy to DuoTrav

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with primary open-angle glaucoma, ocular hypertension or pigment dispersion glaucoma.~* Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Age related.~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DuoTrav (Type: EXPERIMENTAL): One drop in study eye(s) once daily in the evening (at 8:00 PM) for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete